Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Inhaled corticosteriod/long-acting beta-agonist plus Montelukast
Second Affiliated Hospital, School of Medicine, Zhejiang University
Asthma
1 trial -
Innovative Dietary Formulation (Patent ID: CN110250417A)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Insulin
The First People's Hospital of Lianyungang
Gestational Diabetes
1 trial -
Intensity-modulated radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Intensive BP treatment group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Interleukin-2
The First People's Hospital of Lianyungang
Beta Thalassemia Major
1 trial -
Intestinal Microbiota Transplant (IMT) Capsules
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cardiovascular Disease
1 trial -
Intranasal Oxytocin (OT) 24 IU
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healthy Participants
1 trial -
Intraoperative Radiation Therapy in Malignant Cerebral Tumor
The First People's Hospital of Lianyungang
Glioblastoma
1 trial -
Intraoperative identification method
Xijing Hospital
Thyroid Cancer
1 trial -
Intrauterine lavage therapy
The First People's Hospital of Lianyungang
Intrauterine Adhesions
1 trial -
Intravenous Anesthetic Induction with Ciprofol for Painless Colonoscopy in Elderly Patients
The First People's Hospital of Lianyungang
Ciprofol
1 trial -
Intravenous dexmedetomidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Aneurysm Cerebral
1 trial -
Intravenous thrombolysis
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Ischemic Stroke
1 trial -
Intravenous tramadol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Catheter Site Discomfort
1 trial -
Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection
The First People's Hospital of Lianyungang
Small Cell Lung Cancer
1 trial -
Iron Isomaltoside injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Obesity
1 trial -
Iron sucrose, Human Erythropoietin Injection, Vitamin C
The First People's Hospital of Lianyungang
Anemia
1 trial -
Isoniazid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Kidney Transplant Infection
1 trial -
Isosorbide Dinitrate 5 MG
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Post-ERCP Acute Pancreatitis
1 trial -
Itraconazole
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sporotrichosis
1 trial -
Ivarmacitinib tablet
The First People's Hospital of Lianyungang
Polymyalgia Rheumatics (PMR)
1 trial -
Ivosidenib,Venetoclax,gilteritinib,Selinexor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML
1 trial -
JAK Inhibitor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Antisynthetase Syndrome
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources